Updated Jul 16, 2026
Henderson Jane has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $1.21M.
Jane Henderson is a corporate executive known for her role as Chief Financial Officer at multiple biotechnology companies, including Akero Therapeutics, Inc., Apogee Therapeutics, Inc., and CARGO Therapeutics, Inc. She has been involved in various SEC filings related to these companies.
| Role | Chief Financial Officer |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 289 | $83.16 | $24K |
| 2026-05-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 900 | $82.60 | $74K |
| 2026-05-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 811 | $81.02 | $66K |
| 2026-04-18 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale | 2.0K | $90.00 | $180K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.1K | $85.46 | $94K |
| 2026-04-04 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 900 | $84.46 | $76K |
| 2026-03-28 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 2.0K | $85.00 | $170K |
| 2026-03-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 406 | $71.66 | $29K |
| 2026-03-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 994 | $70.45 | $70K |
| 2026-03-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 300 | $69.43 | $21K |
| 2026-03-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 300 | $68.27 | $20K |
| 2026-02-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 100 | $66.89 | $7K |
| 2026-02-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.1K | $66.15 | $73K |
| 2026-02-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 792 | $65.21 | $52K |
| 2025-12-09 | AKRO | Akero Therapeutics, Inc. | D — Derivative transaction | 9.4K | — | |
| 2025-12-05 | APGE | Apogee Therapeutics, Inc. | S — Open-market sale [10b5-1] | 1.5K | $75.00 | $112K |
| 2025-08-12 | AKRO | Akero Therapeutics, Inc. | S — Open-market sale | 3.0K | $47.46 | $142K |
| 2025-08-12 | AKRO | Akero Therapeutics, Inc. | M — Option exercise | 3.0K | $7.01 | $21K |
Jane Henderson is a corporate executive known for her role as Chief Financial Officer at multiple biotechnology companies, including Akero Therapeutics, Inc., Apogee Therapeutics, Inc., and CARGO Therapeutics, Inc. She has been involved in various SEC filings related to these companies.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 16 open-market sales ($1.21M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Henderson Jane profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.